Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences to Present at the 29th Annual ROTH Conference

PR Newswire March 8, 2017

BioDelivery Sciences Secures Debt Financing with CRG

PR Newswire February 23, 2017

BioDelivery Sciences to Hold Analyst and Investor Day to Discuss BELBUCA® Commercialization Plans on February 1st in New York City

PR Newswire January 26, 2017

Research Reports Coverage on Biotech Stocks -- Genetic Technologies, Alder Biopharma, BioDelivery Sciences, and Egalet

PR Newswire January 24, 2017

MonoSol Rx Files Patent Infringement Suit against BioDelivery Sciences International (BDSI)

GlobeNewswire January 13, 2017

BioDelivery Sciences Closes Transaction to Reacquire License to BELBUCA® from Endo Pharmaceuticals

PR Newswire January 9, 2017

BioDelivery Sciences Announces the Hiring of Peter Ginsberg as Vice President of Business Development

PR Newswire December 14, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  December 13, 2016

Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Forecast

Benzinga.com  December 13, 2016

BioDelivery Sciences Announces Clonidine Topical Gel for Painful Diabetic Neuropathy Phase 2b Trial Fails to Meet its Primary Efficacy Endpoint

PR Newswire December 13, 2016

Belbuca Revenue 'Immaterial,' Says JMP On Rx's Return To BioDelivery From Endo International

Benzinga.com  December 9, 2016

BioDelivery Sciences Reacquires License to BELBUCA™ from Endo Pharmaceuticals

PR Newswire December 8, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  November 23, 2016

BioDelivery Sciences to Present at the 28th Annual Piper Jaffray Healthcare Conference

PR Newswire November 23, 2016

Biotech Stocks Under Scanner -- PTC Therapeutics, Arena Pharma, BioDelivery Sciences, and Seres Therapeutics

PR Newswire November 23, 2016

BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2016 Financial Results

PR Newswire November 9, 2016

BioDelivery Sciences to Present at the Stifel 2016 Healthcare Conference

PR Newswire November 8, 2016

BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2016 Financial Results on Wednesday, November 9

PR Newswire November 1, 2016

BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid

PR Newswire October 24, 2016

BioDelivery Sciences Announces Additions to its Board of Directors

PR Newswire October 5, 2016